Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 08.12.2020 | 12:07

Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures

Aladdin Healthcare Technologies SE / Key word(s): Preliminary Results
Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures

08-Dec-2020 / 12:07 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures

Aladdin Healthcare Technologies SE (the "Company") reports that in the course of the preparation of its consolidated annual financial statements under IFRS for the financial year 2019, losses in the amount of EUR 2,989.9k will be accounted for due to an EUR 1,532.2k impairment of financial assets. In 2018 there has been a re-adjustment of expenses relating to intellectual property that were originally deemed by the Company as being eligible for capitalisation in the balance sheet. These losses in the amount of EUR 1,430.6k together with losses from operational activities presumably result in total losses for the financial year 2018 in the amount of EUR 5,391.4. The Company is currently in the process of finalising the financial statements for 2019 which are expected to be approved by the Board of Directors and audited by its auditor after the first two weeks of December.

In 2019 the losses from impairment of assets relate to non-current loans, which is in majority made up of a convertible loan to the Hong Kong licensee of the Company. An impairment charge of EUR 1,532.2k will be applied to the loan as management made the decision not to pursue the terms of the license any further and to cease expenditure on any future development with the Shenzhen Guo Yi Hui Hospital Management Co. The loan is not reasonably recoverable at the balance sheet date, therefore an impairment charge for the full outstanding amount has been applied through the profit and loss. The impairment charge in the amount of EUR 1,532.2k together with losses from operational activities will presumably result in total losses for the financial year 2019 of EUR 2,989.9k.

The retained earnings balance before correction was EUR -3,920.4k in the financial year 2018. After correction of losses from the re-adjustment related to the capitalisation of expenses incurred in the financial year 2018 relating to the software of the Company and other smaller adjustments, the retained earnings were reduced by EUR 2.492.7k to a post adjustment balance of EUR -6.413.1k.

Further preliminary key figures of the 2019 consolidated financial statements are as follows:

Balance sheet:
Total assets: EUR 480.5k (2018: EUR 1,919.0k)
Total Equity: EUR -1,765.8k (2018: EUR 1,463.0k)
Total liabilities: EUR 2,246.2k (2018: EUR 456.0k)

Profit and loss:
Revenues: EUR 0 (2018: EUR 174.5k)
Operating loss: EUR 2,989.9k (2018: EUR 5,391.4k)

Contact:
Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Tel 0307700 140 449
email: info@aladdinid.com
www.aladdinid.com


08-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

„Eine Investition in Mutares lohnt sich“

Mutares ist ein europaweit führender Private-Equity-Investor, der sich auf Sondersituationen wie Abspaltungen von großen Konzernen oder Turnaround- und Nachfolgesituationen spezialisiert hat. Ziel ist es, mit den Investments einen Return auf das eingesetzte Kapital von 7 bis 10 zu erzielen. Mit der jüngsten Mittelfristprognose hat der Münchner Finanzinvestor auf Basis von 5 Mrd. Euro Konzernumsatz eine Nettorendite für die börsennotierte Holding von 1,8 bis 2,2 % in Aussicht gestellt. In der Mitte der Zielspanne wird somit ein Nettogewinn von circa 100 Mio. Euro anvisiert. Hauck & Aufhäuser hat in der jüngsten Analyse ein Buy-Rating mit Kursziel für Mutares von 37,50 Euro ausgegeben.

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Vonovia on the election of the Berlin House of Representatives and the referendum to expropriate Deutsche Wohnen & Co.: Berlin needs a new way of working together on housing

27. September 2021, 11:07

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

Schloss Wachenheim AG

Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Kaufen

28. September 2021